Jazz Pharmaceuticals PLC (JAZZ)
| Market Cap | 9.34B |
| Revenue (ttm) | 2.28B |
| Net Income (ttm) | 179.19M |
| Shares Out | 55.55M |
| EPS (ttm) | 3.16 |
| PE Ratio | 53.04 |
| Forward PE | 9.99 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $167.71 |
| Previous Close | $165.81 |
| Change ($) | 1.90 |
| Change (%) | 1.15% |
| Day's Open | 166.09 |
| Day's Range | 165.00 - 168.12 |
| Day's Volume | 677,230 |
| 52-Week Range | 87.74 - 168.12 |
Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.
DUBLIN, Jan. 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 39th Annual J.P. Morgan Healthcare ...
Jazz (JAZZ) initiates the submission of a BLA to the FDA for the marketing approval of JZP-458 for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma.
JAZZ announces the failure of a combination regimen of SCLC drug, Zepzelca, to meet primary endpoint in a late-stage study. However, overall study data seems promising for the drug.
DUBLIN, Dec. 3, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ), along with its partner, PharmaMar (MSE: PHM), today announce results from the ATLANTIS Phase 3 multicenter, random...
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Is Jazz Pharmaceuticals (JAZZ) a great pick from the value investor's perspective right now? Read on to know more.
DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Jennifer Cook and Mark D. Smith, M.D. have been appointed to the Company's Board of Directors...
DUBLIN, Nov. 10, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the following virtual healthcare confe...
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our i...
DUBLIN, Nov. 5, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 11 company-sponsored abstracts, in addition to two abstracts from collaboration trials with Th...
The shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) are up 5.9% at $156 at last check, after a third-quarter earnings and revenue beat.
Jazz Pharmaceuticals (JAZZ) reports better-than-expected third-quarter 2020 earnings and revenues and ups its sales guidance for 2020.
Jazz Pharmaceuticals plc's (JAZZ) CEO Bruce Cozadd on Q3 2020 Results - Earnings Call Transcript
Jazz (JAZZ) delivered earnings and revenue surprises of 6.95% and 4.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) moved higher by 7.9% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 5.12% year over ye...
DUBLIN, Nov. 2, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2020 and updated its 2020 financial guidance. "We delive...
Jazz Pharmaceuticals (NASDAQ: JAZZ) releases its next round of earnings this Monday, November 02. Here is Benzinga's essential guide to Jazz Pharmaceuticals's Q3 earnings report.
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
It is almost hard to believe, in what has been one of the most unbelievable years in recent history, that Halloween is this weekend and Thanksgiving is right around the corner.
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN and STAMFORD, Conn., Oct. 26, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) ("SpringWorks") today announced that Jazz Ph...
DUBLIN, Oct. 20, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the publication of the global Phase 3 double-blind, placebo-controlled, randomized-withdrawal, mul...
DUBLIN, Oct. 19, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 third quarter financial results on Monday, November 2, 2020, after th...
A second term for Trump would be music to the ears of these four companies.
Nearby support on the charts suggests that the pharmaceuticals sector could be one to watch over the last few months of 2020.
Jazz Pharmaceuticals: Long-Term Prospects Jazz Up A Modest Upside
Jazz Pharmaceuticals (JAZZ) posts favorable top-line results from a phase III study on Xywav oral solution, which is being evaluated to treat adult patients with idiopathic hypersomnia. Shares...
Jazz Pharmaceuticals posted positive final-phase trials data for both effectiveness and safety for a drug therapy to treat a sleep disorder, sending JAZZ stock jumping back into a buy zone. Th...
DUBLIN, Oct. 8, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive top-line results from the Phase 3 double-blind, multicenter, placebo-controlled, randomize...
Drug developers don't get much cheaper than this.
In case of a flash sale, scoop up shares of companies that are bound to bounce back.
A Relative Strength Rating upgrade for Jazz Pharmaceuticals shows improving technical performance. The post Stock Upgrades: Jazz Pharmaceuticals Shows Rising Relative Strength appeared first o...
Despite a poor performance of late, this biotech stock could bounce back.
DUBLIN, Sept. 17, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Find the Right Fit (FindTheRightFit-sAML.com), a U.S.
DUBLIN, Sept. 15, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its support of the American Heart Association's sleep health educational content aimed at improvi...
SAN FRANCISCO--(BUSINESS WIRE)--Cleave Therapeutics Announces Research Collaboration with Jazz Pharmaceuticals in Acute Myeloid Leukemia (AML)
DUBLIN, Sept. 9, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company has signed a new research collaboration agreement with Redx Pharma plc (AIM: REDX...
DUBLIN, Sept. 8, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentations at the following virtual investor confer...
Earnings yield is a useful ratio for investors who have exposure to both stocks and bonds.
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
These shell companies allow the businesses they acquire to go public much more quickly than an IPO would. Is it time to buy in?
Jazz (JAZZ) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
DUBLIN, Aug. 27, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 10 abstracts will be presented at Virtual SLEEP 2020, the 34th annual meeting of the Associat...
Jazz Pharmaceuticals (JAZZ) reports better-than-expected second-quarter 2020 earnings and revenues. It raises its guidance for 2020.
The drugmaker delivered solid growth in Q2 and upped its full-year outlook.
Jazz Pharmaceuticals plc (JAZZ) CEO Bruce Cozadd on Q2 2020 Results - Earnings Call Transcript
Jazz (JAZZ) delivered earnings and revenue surprises of 9.76% and 11.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
About JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adu... [Read more...]
| Industry Biotechnology | IPO Date Jun 1, 2007 |
| CEO Bruce C. Cozadd | Employees 1,620 |
| Stock Exchange NASDAQ | Ticker Symbol JAZZ |
Financial Performance
In 2019, JAZZ's revenue was $2.16 billion, an increase of 14.32% compared to the previous year's $1.89 billion. Earnings were $523.37 million, an increase of 17.06%.
Analyst Forecasts
According to 20 analysts, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is 181.74, which is an increase of 8.37% from the latest price.